查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1860014

DNA疫苗：全球市场份额和排名、总收入和需求预测（2025-2031年）

DNA Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 90 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球DNA疫苗市场预计在2024年达到53.78亿美元，预计到2031年将达到89.75亿美元，在预测期（2025-2031年）内以7.7%的复合年增长率增长。

DNA疫苗是利用重组DNA技术将编码病原体特定抗原的质体或其他DNA载体导入宿主生物体，使宿主细胞能够转录和翻译这些抗原，进而诱发特异性免疫反应的疫苗。与传统的灭活疫苗或减毒疫苗相比，DNA疫苗具有设计灵活、生产週期短、安全性较高以及不存在病原体完全传播风险等优势。由于其具有快速客製化、大规模生产和相对易于储存的潜力，DNA疫苗在感染疾病预防、肿瘤免疫治疗以及快速应对公共卫生威胁方面展现出巨大的应用前景，并已成为全球生物製药公司、政府和研究机构关注的重点。

鑑于全球公共卫生需求日益增长、感染疾病病变种频繁出现、癌症发病率上升以及抗菌素抗药性蔓延，DNA疫苗正日益被视为下一代疫苗和免疫疗法的核心解决方案。各国政府和国际组织已大幅增加针对新冠病毒、疟疾和登革热等新兴病原体的研究经费，为DNA疫苗计划提供持续的政策和资金支持。同时，合成生物学、基因合成、质体设计和免疫抗原性优化的突破缩短了从实验室检验到临床阶段的时间，并降低了失败成本。在临床试验中，一些DNA疫苗候选产品展现出良好的安全性和免疫反应（包括T细胞反应），提振了市场和投资人的信心。此外，由于病毒性和寄生虫性疾病对畜牧业和水产养殖业造成了毁灭性损失，兽用疫苗的需求持续增长。 DNA疫苗因其低温运输和运输优势而备受青睐，使这些市场成为重要的早期商业化基础。市场估值预测显示，未来十年DNA疫苗产业将以约6-7%的复合年增长率成长，市场规模将翻倍，从研发到生产和分销的整个过程都将创造巨大的利润潜力。

然而，DNA疫苗在普及应用前仍面临许多挑战。首先，免疫抗原性。目前，人们对DNA疫苗在人体内的免疫反应强度和持久性仍存在不确定性，尤其与基于蛋白质和病毒载体的疫苗相比。一些处于早期试验阶段的候选疫苗尚未诱发足够的抗体或持久的T细胞反应。其次，监管核准流程十分严格。每个司法管辖区都对安全性、长期影响和基因插入风险提出了严格的要求，这可能会延长上市时间并增加成本。第三，成本和生产复杂性都很高，尤其是在质体生产、纯化、递送系统以及储存和运输（包括低温或亚低温链）方面。高标准的GMP设施和严格的品管至关重要，因为任何缺陷都可能影响疫苗的稳定性和安全性。第四，市场教育和接受度至关重要。医疗专业人员、患者和公共卫生机构仍处于学习阶段，对副作用和长期结果的不确定性可能会导致犹豫不决，从而降低疫苗的普及率。

在下游应用领域，预防性应用（针对感染疾病）仍然是主要需求来源，尤其是在地方性流行地区或现有疫苗供应不足的地区。自新冠疫情爆发以来，初免-加强免疫、加强免疫和异源免疫策略重新激发了人们对DNA疫苗的兴趣，使其成为具有高稳定性和快速生产能力的补充工具。治疗性应用正在迅速扩展：癌症疫苗、慢性病毒感染疾病疫苗（例如HIV、HBV/HCV）以及寄生虫和真菌疾病疫苗均处于临床试验或早期研究阶段。在兽医学领域，家禽、水产养殖和畜牧业对DNA疫苗的需求强劲，因为它们可以减少疾病损失和抗生素使用，并提高生产力。公共卫生和政府采购机构越来越关注疫苗的全生命週期成本（运输和储存基础设施、剂量、耐久性和广泛的免疫覆盖范围），这进一步增强了DNA疫苗的吸引力，因为它们具有高稳定性、接种週期少和免疫反应广等优点。

本报告旨在对全球DNA疫苗市场进行全面分析，重点关注总收入、市场份额和主要企业的排名，以及按地区/国家、类型和应用对DNA疫苗进行分析。

本报告以2024年为基准年，按销售收入提供DNA疫苗市场规模、估计值和预测，并包含2020年至2031年的历史数据和预测数据。我们运用定量和定性分析，帮助读者制定业务/成长策略，评估市场竞争格局，分析自身在当前市场中的地位，并就DNA疫苗做出明智的商业决策。

市场区隔

公司

  • Merck
  • GSK
  • Sanofi
  • Zoties
  • Elanco
  • Boehringer-Ingelheim
  • Indian Immunologicals
  • Plumbline Life Sciences

按类型分類的细分市场

  • 重组蛋白疫苗
  • 基因疫苗

应用领域

  • 人类
  • 动物

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for DNA Vaccines was estimated to be worth US$ 5378 million in 2024 and is forecast to a readjusted size of US$ 8975 million by 2031 with a CAGR of 7.7% during the forecast period 2025-2031.

DNA vaccines are vaccines that use recombinant DNA technology, introducing plasmids or other DNA vectors encoding specific antigens of a pathogen into the host organism, where host cells transcribe and translate the antigen, thus eliciting a specific immune response. Compared to traditional inactivated or attenuated vaccines, DNA vaccines offer flexibility in design, shorter production cycles, relatively high safety, and no risk of transmission of the complete pathogen. They are particularly promising in prevention of infectious diseases, tumor immunotherapy, and rapid response to public health threats, thanks to their capability for rapid customization, large-scale production, and comparatively easier storage, making them a key focus for global biopharma companies, governments, and research institutions.

Amid growing global public health needs, frequent emergence of infectious disease variants, rising cancer incidence, and escalating antimicrobial resistance, DNA vaccines are increasingly viewed as core next-generation vaccine and immunotherapy solutions. Governments and international agencies have significantly increased funding for research targeting emerging pathogens (such as coronaviruses, malaria, dengue etc.), thereby providing continuous policy and financial support for DNA vaccine projects. At the same time, leaps in synthetic biology, gene synthesis, plasmid design and immunogenicity optimization have shortened timelines from lab validation to clinical stages, reducing failure costs. In clinical trials, multiple DNA vaccine candidates have shown positive safety profiles and immune responses (including T cell responses), boosting the confidence of markets and investors. Moreover, demand in the animal health / veterinary vaccine sector continues to accelerate, as viral and parasitic diseases exact heavy losses in livestock/aquaculture, and DNA vaccines' advantages in cold chain and transport make them particularly appealing, making those markets important early commercial footholds. Market valuation forecasts suggest the DNA vaccine industry will grow at a roughly 6-7% compound annual growth rate over the next decade, with market size likely to double, yielding large profit potential along the entire chain-from R&D through manufacturing and distribution.

However, for DNA vaccines to become mainstream there are substantial challenges. First is immunogenicity: the strength and durability of immune responses in humans, especially relative to protein-based or viral vector vaccines, remain uncertain; some candidates in early trials have not elicited sufficiently high neutralizing antibodies or lasting T cell responses. Second, regulatory approval processes are stringent; different jurisdictions impose very cautious requirements about safety, long-term effects, gene insertion risks, etc., which may lengthen time to market and raise costs. Third, cost and production complexity are high, particularly in plasmid production, purification, delivery systems, and storage/transport (including cold or semi-cold chain) steps. High standard GMP facilities and rigorous quality control are essential; any lapse can impact stability and safety. Fourth, market education and acceptance: medical practitioners, patients, and public health bodies are still learning; uncertainty around side effects or long-term outcomes may fuel hesitancy and reduce uptake.

Downstream, preventive applications (for infectious diseases) remain the dominant demand, especially in regions with frequent outbreaks or under-served by existing vaccine supply. Post-COVID-19, prime-boost regimens, booster shots, and heterologous immunization strategies are giving DNA vaccines renewed interest as stable, rapidly producible complements. Therapeutic applications are growing fast: cancer vaccines, chronic viral infections (e.g. HIV, HBV/HCV), parasitic/fungal disease vaccines are under clinical or early stage research. In the veterinary sector, demand is robust in poultry, aquaculture, and livestock for DNA vaccines that reduce disease losses, antibiotic use, and enhance yield. Public health bodies and government purchasers increasingly focus on total life-cycle cost: transportation & storage infrastructure, dose volume, durability, breadth of immune coverage-all of which amplify the attractiveness of DNA vaccines that are stable, require fewer doses, and have broad immune responses.

This report aims to provide a comprehensive presentation of the global market for DNA Vaccines, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of DNA Vaccines by region & country, by Type, and by Application.

The DNA Vaccines market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DNA Vaccines.

Market Segmentation

By Company

  • Merck
  • GSK
  • Sanofi
  • Zoties
  • Elanco
  • Boehringer-Ingelheim
  • Indian Immunologicals
  • Plumbline Life Sciences

Segment by Type

  • Recombinant Protein Vaccine
  • Gene-Based Vaccine

Segment by Application

  • Human
  • Animal

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of DNA Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of DNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of DNA Vaccines in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 DNA Vaccines Product Introduction
  • 1.2 Global DNA Vaccines Market Size Forecast (2020-2031)
  • 1.3 DNA Vaccines Market Trends & Drivers
    • 1.3.1 DNA Vaccines Industry Trends
    • 1.3.2 DNA Vaccines Market Drivers & Opportunity
    • 1.3.3 DNA Vaccines Market Challenges
    • 1.3.4 DNA Vaccines Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global DNA Vaccines Players Revenue Ranking (2024)
  • 2.2 Global DNA Vaccines Revenue by Company (2020-2025)
  • 2.3 Key Companies DNA Vaccines Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies DNA Vaccines Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of DNA Vaccines
  • 2.6 DNA Vaccines Market Competitive Analysis
    • 2.6.1 DNA Vaccines Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by DNA Vaccines Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DNA Vaccines as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Recombinant Protein Vaccine
    • 3.1.2 Gene-Based Vaccine
  • 3.2 Global DNA Vaccines Sales Value by Type
    • 3.2.1 Global DNA Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global DNA Vaccines Sales Value, by Type (2020-2031)
    • 3.2.3 Global DNA Vaccines Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Human
    • 4.1.2 Animal
  • 4.2 Global DNA Vaccines Sales Value by Application
    • 4.2.1 Global DNA Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global DNA Vaccines Sales Value, by Application (2020-2031)
    • 4.2.3 Global DNA Vaccines Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global DNA Vaccines Sales Value by Region
    • 5.1.1 Global DNA Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global DNA Vaccines Sales Value by Region (2020-2025)
    • 5.1.3 Global DNA Vaccines Sales Value by Region (2026-2031)
    • 5.1.4 Global DNA Vaccines Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America DNA Vaccines Sales Value, 2020-2031
    • 5.2.2 North America DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe DNA Vaccines Sales Value, 2020-2031
    • 5.3.2 Europe DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific DNA Vaccines Sales Value, 2020-2031
    • 5.4.2 Asia Pacific DNA Vaccines Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America DNA Vaccines Sales Value, 2020-2031
    • 5.5.2 South America DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa DNA Vaccines Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa DNA Vaccines Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions DNA Vaccines Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions DNA Vaccines Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States DNA Vaccines Sales Value, 2020-2031
    • 6.3.2 United States DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe DNA Vaccines Sales Value, 2020-2031
    • 6.4.2 Europe DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China DNA Vaccines Sales Value, 2020-2031
    • 6.5.2 China DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan DNA Vaccines Sales Value, 2020-2031
    • 6.6.2 Japan DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea DNA Vaccines Sales Value, 2020-2031
    • 6.7.2 South Korea DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia DNA Vaccines Sales Value, 2020-2031
    • 6.8.2 Southeast Asia DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia DNA Vaccines Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India DNA Vaccines Sales Value, 2020-2031
    • 6.9.2 India DNA Vaccines Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India DNA Vaccines Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Merck
    • 7.1.1 Merck Profile
    • 7.1.2 Merck Main Business
    • 7.1.3 Merck DNA Vaccines Products, Services and Solutions
    • 7.1.4 Merck DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Merck Recent Developments
  • 7.2 GSK
    • 7.2.1 GSK Profile
    • 7.2.2 GSK Main Business
    • 7.2.3 GSK DNA Vaccines Products, Services and Solutions
    • 7.2.4 GSK DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.2.5 GSK Recent Developments
  • 7.3 Sanofi
    • 7.3.1 Sanofi Profile
    • 7.3.2 Sanofi Main Business
    • 7.3.3 Sanofi DNA Vaccines Products, Services and Solutions
    • 7.3.4 Sanofi DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Sanofi Recent Developments
  • 7.4 Zoties
    • 7.4.1 Zoties Profile
    • 7.4.2 Zoties Main Business
    • 7.4.3 Zoties DNA Vaccines Products, Services and Solutions
    • 7.4.4 Zoties DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Zoties Recent Developments
  • 7.5 Elanco
    • 7.5.1 Elanco Profile
    • 7.5.2 Elanco Main Business
    • 7.5.3 Elanco DNA Vaccines Products, Services and Solutions
    • 7.5.4 Elanco DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Elanco Recent Developments
  • 7.6 Boehringer-Ingelheim
    • 7.6.1 Boehringer-Ingelheim Profile
    • 7.6.2 Boehringer-Ingelheim Main Business
    • 7.6.3 Boehringer-Ingelheim DNA Vaccines Products, Services and Solutions
    • 7.6.4 Boehringer-Ingelheim DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Boehringer-Ingelheim Recent Developments
  • 7.7 Indian Immunologicals
    • 7.7.1 Indian Immunologicals Profile
    • 7.7.2 Indian Immunologicals Main Business
    • 7.7.3 Indian Immunologicals DNA Vaccines Products, Services and Solutions
    • 7.7.4 Indian Immunologicals DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Indian Immunologicals Recent Developments
  • 7.8 Plumbline Life Sciences
    • 7.8.1 Plumbline Life Sciences Profile
    • 7.8.2 Plumbline Life Sciences Main Business
    • 7.8.3 Plumbline Life Sciences DNA Vaccines Products, Services and Solutions
    • 7.8.4 Plumbline Life Sciences DNA Vaccines Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Plumbline Life Sciences Recent Developments

8 Industry Chain Analysis

  • 8.1 DNA Vaccines Industrial Chain
  • 8.2 DNA Vaccines Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 DNA Vaccines Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 DNA Vaccines Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. DNA Vaccines Market Trends
  • Table 2. DNA Vaccines Market Drivers & Opportunity
  • Table 3. DNA Vaccines Market Challenges
  • Table 4. DNA Vaccines Market Restraints
  • Table 5. Global DNA Vaccines Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global DNA Vaccines Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies DNA Vaccines Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies DNA Vaccines Product Type
  • Table 9. Key Companies Time to Begin Mass Production of DNA Vaccines
  • Table 10. Global DNA Vaccines Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DNA Vaccines as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global DNA Vaccines Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global DNA Vaccines Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global DNA Vaccines Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global DNA Vaccines Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global DNA Vaccines Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global DNA Vaccines Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global DNA Vaccines Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global DNA Vaccines Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global DNA Vaccines Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global DNA Vaccines Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global DNA Vaccines Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global DNA Vaccines Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global DNA Vaccines Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global DNA Vaccines Sales Value by Region (2020-2025) & (%)
  • Table 27. Global DNA Vaccines Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions DNA Vaccines Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions DNA Vaccines Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions DNA Vaccines Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Merck Basic Information List
  • Table 32. Merck Description and Business Overview
  • Table 33. Merck DNA Vaccines Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in DNA Vaccines Business of Merck (2020-2025)
  • Table 35. Merck Recent Developments
  • Table 36. GSK Basic Information List
  • Table 37. GSK Description and Business Overview
  • Table 38. GSK DNA Vaccines Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in DNA Vaccines Business of GSK (2020-2025)
  • Table 40. GSK Recent Developments
  • Table 41. Sanofi Basic Information List
  • Table 42. Sanofi Description and Business Overview
  • Table 43. Sanofi DNA Vaccines Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in DNA Vaccines Business of Sanofi (2020-2025)
  • Table 45. Sanofi Recent Developments
  • Table 46. Zoties Basic Information List
  • Table 47. Zoties Description and Business Overview
  • Table 48. Zoties DNA Vaccines Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in DNA Vaccines Business of Zoties (2020-2025)
  • Table 50. Zoties Recent Developments
  • Table 51. Elanco Basic Information List
  • Table 52. Elanco Description and Business Overview
  • Table 53. Elanco DNA Vaccines Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in DNA Vaccines Business of Elanco (2020-2025)
  • Table 55. Elanco Recent Developments
  • Table 56. Boehringer-Ingelheim Basic Information List
  • Table 57. Boehringer-Ingelheim Description and Business Overview
  • Table 58. Boehringer-Ingelheim DNA Vaccines Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in DNA Vaccines Business of Boehringer-Ingelheim (2020-2025)
  • Table 60. Boehringer-Ingelheim Recent Developments
  • Table 61. Indian Immunologicals Basic Information List
  • Table 62. Indian Immunologicals Description and Business Overview
  • Table 63. Indian Immunologicals DNA Vaccines Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in DNA Vaccines Business of Indian Immunologicals (2020-2025)
  • Table 65. Indian Immunologicals Recent Developments
  • Table 66. Plumbline Life Sciences Basic Information List
  • Table 67. Plumbline Life Sciences Description and Business Overview
  • Table 68. Plumbline Life Sciences DNA Vaccines Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in DNA Vaccines Business of Plumbline Life Sciences (2020-2025)
  • Table 70. Plumbline Life Sciences Recent Developments
  • Table 71. Key Raw Materials Lists
  • Table 72. Raw Materials Key Suppliers Lists
  • Table 73. DNA Vaccines Downstream Customers
  • Table 74. DNA Vaccines Distributors List
  • Table 75. Research Programs/Design for This Report
  • Table 76. Key Data Information from Secondary Sources
  • Table 77. Key Data Information from Primary Sources

List of Figures

  • Figure 1. DNA Vaccines Product Picture
  • Figure 2. Global DNA Vaccines Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global DNA Vaccines Sales Value (2020-2031) & (US$ Million)
  • Figure 4. DNA Vaccines Report Years Considered
  • Figure 5. Global DNA Vaccines Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by DNA Vaccines Revenue in 2024
  • Figure 7. DNA Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Recombinant Protein Vaccine Picture
  • Figure 9. Gene-Based Vaccine Picture
  • Figure 10. Global DNA Vaccines Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global DNA Vaccines Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Human
  • Figure 13. Product Picture of Animal
  • Figure 14. Global DNA Vaccines Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global DNA Vaccines Sales Value Market Share by Application, 2024 & 2031
  • Figure 16. North America DNA Vaccines Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific DNA Vaccines Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa DNA Vaccines Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions DNA Vaccines Sales Value (%), (2020-2031)
  • Figure 27. United States DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 30. Europe DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 33. China DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Japan DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 39. South Korea DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Southeast Asia DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 45. India DNA Vaccines Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India DNA Vaccines Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India DNA Vaccines Sales Value by Application (%), 2024 VS 2031
  • Figure 48. DNA Vaccines Industrial Chain
  • Figure 49. DNA Vaccines Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed